Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00091975 | Zemplar® Capsule in Reducing Serum Intact Parathyroid Hormone Levels in Chronic Kidney Disease Stage 5 Subjects on Hemodialysis or Peritoneal Dialysis | PHASE3 | COMPLETED | 78 | — | — | Aug 1, 2004 | - | Jan 19, 2011 | 16 | United States |
| Name | Type | Description |
|---|---|---|
| Zemplar Capsule | DRUG | - |
Inclusion Criteria * Subject was at least 18 years of age, diagnosed with CKD Stage 5 and undergoing HD or PD. * If female, subject was either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hys...